Value Lens: How the Carlyle deal prices SeQuent over its overseas peers

By Ankit Agarwal

  • 14 May 2020
Premium
Credit: 123RF.com

The Carlyle Group’s deal to take control of SeQuent Scientific Ltd appears to have come at a premium for the private equity firm when compared with the Indian animal healthcare company’s much bigger peers overseas. The PE firm has agreed to acquire up to 74% of SeQuent for Rs 1,580 crore ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.